NetworkNewsBreaks – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) Obtains FDA Clearance to Commence Clinical Study of Parkinson’s Disease Treatment
Shares of Titan Pharmaceuticals (NASDAQ: TTNP) are 5% higher after the company this morning said its Investigational New Drug (IND) application for its ropinirole implant has been cleared by the U.S. Food and Drug Administration (FDA). The company is now permitted to move forward with the phase 1/2 clinical study in patients. Developed utilizing Titan's ProNeura™ technology, the ropinirole implant is intended for the long-term, continuous delivery of ropinirole HCL for the treatment of signs and symptoms of Parkinson's disease. "Our ropinirole implant is designed to provide continuous, non-fluctuating therapeutic levels of medication for up to three months, potentially offering…